TWST financials
Twist Bioscience Corporation · end-of-day data as of Nov 13, 2026
Twist Bioscience
$111.60-2.3%
PT $145.70 +30.6%▲ 3
- PT$145.70 +30.6%
- ConsensusBuy · 13
- Sector▲ +15.9%
Neutral
- Earnings in80d
- RSI38
- Support-50.2%
- Resistance+55.4%
- Off 52w high-49.2%
- Volume0.8x
- Bollingerlower half
- News1.00
- Trendsideways
- 52w range$23–$220
- ATR+15.1%
- Off ATH-49.2%
▼ 4
- Insiders-$99.86M
- MAs1 of 4
- MA20×50Death 9d ago
- MACD-3.21
Updates with the 15-min delayed price. Not a forecast or investment advice.
Valuation
- P/E—
- P/E vs own—
- P/E vs sector—
- FCF yield—
- Market cap$7.35B
Quarterly results
Q4 FY2026: Revenue +27.9% year over year, operating margin -25.0%.
RevenueFree cash flow
| Q4 FY2026 | Sep 30, 2026 | $127M | -0.31 | — | 53.1% | -25.0% | -16.3% |
| Q3 FY2026 | Jun 30, 2026 | $118M | -0.56 | -$8.55M | 52.8% | -30.6% | -29.6% |
| Q2 FY2026 | Mar 31, 2026 | $111M | -0.71 | -$25.55M | 51.6% | -34.9% | -39.8% |
| Q1 FY2026 | Dec 31, 2025 | $104M | -0.50 | -$34.79M | 52.0% | -31.7% | -29.4% |
| Q4 FY2025 | Sep 30, 2025 | $99.01M | -0.45 | -$24.24M | 51.3% | -30.2% | -27.4% |
| Q3 FY2025 | Jun 30, 2025 | $96.06M | 0.33 | -$10.56M | 53.4% | -31.4% | 21.2% |
| Q2 FY2025 | Mar 31, 2025 | $92.79M | -0.66 | -$17.13M | 49.6% | -44.8% | -42.4% |
| Q1 FY2025 | Dec 31, 2024 | $88.71M | -0.53 | -$23.7M | 48.3% | -39.1% | -35.6% |
| Q4 FY2024 | Sep 30, 2024 | $84.71M | -0.60 | -$17.32M | 45.1% | -42.5% | -40.9% |
| Q3 FY2024 | Jun 30, 2024 | $81.46M | -1.47 | -$7.34M | 43.3% | -109.2% | -105.0% |
| Q2 FY2024 | Mar 31, 2024 | $75.3M | -0.79 | -$20.03M | 41.0% | -64.9% | -60.4% |
| Q1 FY2024 | Dec 31, 2023 | $71.5M | -0.75 | -$24.48M | 40.5% | -65.7% | -60.2% |